Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with ...

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...

Boehringer Ingelheim advances IL-11 ... • BI 765423 has been developed to target IL-11, a key driver of fibrosis • The potential first-in-class inhibitor is an acquired asset from Enleofen with ...

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its ...

The first patient received dosing at Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.

Booster Therapeutics (Germany) focuses on developing small-molecule proteasome activators for neurodegenerative disease using ...

New research is shedding light on surprising ways to reduce chronic inflammation—including suggestions as simple as flossing ...

A new study published in the Journal of the European Academy of Dermatology & Venerology showed that in children with severe ...

EQT Life Sciences is pleased to announce that its LSP Dementia Fund has co-led a EUR 51 million Series B in Exciva (the "Company"), a clinical-stage biopharmaceutical company developing novel ...

A recent study published in the journal Breast Cancer Research has found that adolescent girls who engage in regular organised physical activity show favourable changes in breast tissue composition ...

Anti-inflammatory treatment reduced depressive symptoms and anhedonia in patients with elevated inflammation. Learn more.